Cefmenoxime
Cefmax (cefmenoxime) is a small molecule pharmaceutical. Cefmenoxime was first approved as Cefmax on 1987-12-30.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefmenoxime hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CEFMAX | TAP Pharmaceuticals | N-050571 DISCN | 1987-12-30 | 3 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
123 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Surgical wound infection | D013530 | 2 | — | 1 | 7 | 3 | 13 | ||
| Infections | D007239 | EFO_0000544 | 3 | 1 | 3 | 2 | 4 | 12 | |
| Wound infection | D014946 | — | — | — | 5 | 4 | 9 | ||
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | 3 | 1 | 1 | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | 3 | — | 5 |
| Antibiotic prophylaxis | D019072 | — | — | — | 2 | 3 | 5 | ||
| Osteomyelitis | D010019 | EFO_0003102 | M86 | — | — | 1 | 2 | — | 3 |
| Staphylococcal infections | D013203 | A49.01 | — | — | 1 | 1 | 1 | 3 | |
| Endometritis | D004716 | EFO_1001312 | — | — | — | 1 | 1 | 2 | |
| Infectious arthritis | D001170 | EFO_1001351 | M00 | — | — | — | 2 | — | 2 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | 1 | — | 1 | 3 |
| Sepsis | D018805 | A41.9 | 1 | — | 1 | — | — | 2 | |
| Hemopneumothorax | D006468 | EFO_1000963 | J94.2 | — | 1 | 1 | — | — | 1 |
| Pneumothorax | D011030 | J93.11 | — | 1 | 1 | — | — | 1 | |
| Keratitis | D007634 | H16 | — | — | 1 | — | — | 1 | |
| Premature rupture fetal membranes | D005322 | HP_0001788 | O42 | — | — | 1 | — | — | 1 |
| Gram-positive bacterial infections | D016908 | — | — | 1 | — | — | 1 | ||
| Implant capsular contracture | D057910 | — | — | 1 | — | — | 1 | ||
| Prostatic neoplasms | D011471 | C61 | — | — | 1 | — | — | 1 | |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Fever | D005334 | HP_0001945 | R50.9 | — | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | — | — | — | 1 |
| Cross infection | D003428 | — | 1 | — | — | — | 1 | ||
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 3 | 3 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 2 | 2 |
| Closed fractures | D005596 | — | — | — | — | 2 | 2 | ||
| Replacement arthroplasty knee | D019645 | — | — | — | — | 1 | 1 | ||
| Dentofacial deformities | D063169 | — | — | — | — | 1 | 1 | ||
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | — | — | — | 1 | 1 |
| Parathyroid diseases | D010279 | E21.5 | — | — | — | — | 1 | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 1 | ||
| Necrotizing enterocolitis | D020345 | EFO_0003928 | K55.3 | — | — | — | — | 1 | 1 |
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CEFMENOXIME |
| INN | cefmenoxime |
| Description | Cefmenoxime is a third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position. It has a role as an antibacterial drug. It is a conjugate acid of a cefmenoxime(1-). |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@H]12)c1csc(N)n1 |
Identifiers
| PDB | — |
| CAS-ID | 65085-01-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201224 |
| ChEBI ID | 55490 |
| PubChem CID | 9570757 |
| DrugBank | DB00267 |
| UNII ID | KBZ4844CXN (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 428 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,506 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more